An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
MERCK-MK-5684-01APhase I/IIOPEN TO ACCRUAL
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)